The incidence, characteristics, managements and outcomes of anaphylaxis in pregnancy:a population-based descriptive study by McCall, Stephen J et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The incidence, characteristics, managements and outcomes of
anaphylaxis in pregnancy
Citation for published version:
McCall, SJ, Bunch, KJ, Brocklehurst, P, D'Arcy, R, Hinshaw, K, Kurinczuk, JJ, Lucas, DN, Stenson, B,
Tuffnell, D & Knight, M 2017, 'The incidence, characteristics, managements and outcomes of anaphylaxis in
pregnancy: a population-based descriptive study', BJOG: An International Journal of Obstetrics and
Gynaecology. https://doi.org/10.1111/1471-0528.15041
Digital Object Identifier (DOI):
10.1111/1471-0528.15041
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
BJOG: An International Journal of Obstetrics and Gynaecology
Publisher Rights Statement:
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
The incidence, characteristics, management and
outcomes of anaphylaxis in pregnancy: a
population-based descriptive study
SJ McCall,a KJ Bunch,a P Brocklehurst,a,b R D’Arcy,c K Hinshaw,d JJ Kurinczuk,a DN Lucas,e
B Stenson,f DJ Tuffnell,g M Knighta
a Policy Research Unit in Maternal Health and Care, National Perinatal Epidemiology Unit (NPEU), Nuffield Department of Population
Health, University of Oxford, Oxford, UK b Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK c Nuffield
Department of Obstetrics and Gynaecology, John Radcliffe Hospital, University of Oxford, Oxford, UK d Department of Obstetrics and
Gynaecology, Sunderland Royal Hospital, Sunderland, UK e Department of Anaesthetics, Northwick Park Hospital, London, UK
f Neonatal Unit, Royal Infirmary of Edinburgh, Edinburgh, UK g Teaching Hospitals Foundation NHS Trust, Bradford, UK
Correspondence: S McCall, Policy Research Unit in Maternal Health and Care, National Perinatal Epidemiology Unit, Nuffield Department of
Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK. Email stephen.mccall@npeu.ox.ac.uk
Accepted 21 November 2017. Published Online 4 January 2018.
Objective The aim of this study was to estimate the incidence of
anaphylaxis in pregnancy and describe the management and
outcomes in the UK.
Design A population-based descriptive study using the UK
Obstetric Surveillance System (UKOSS).
Setting All consultant-led maternity units in the UK.
Population All pregnant women who had anaphylaxis between 1
October 2012 and 30 September 2015. Anaphylaxis was defined as
a severe, life-threatening generalised or systemic hypersensitivity
reaction.
Methods Prospective case notification using UKOSS.
Main outcome measures Maternal mortality, severe maternal
morbidity, neonatal mortality and severe neonatal morbidity.
Results There were 37 confirmed cases of anaphylaxis in
pregnancy, giving an estimated incidence of 1.6 (95% CI: 1.1–
2.2) per 100 000 maternities. Four cases of anaphylaxis were in
women with known penicillin allergies: two received co-
amoxiclav and two cephalosporins. Twelve women had
anaphylaxis following prophylactic use of antibiotics at the time
of a caesarean delivery. Prophylactic use of antibiotics for
Group B streptococcal infection accounted for anaphylaxis in
one woman. Two women died (5%), 14 (38%) women were
admitted to intensive care and seven women (19%) had one or
more additional severe maternal morbidities, which included
three haemorrhagic events, two cardiac arrests, one thrombotic
event and one pneumonia. No infants died; however, in those
infants whose mother had anaphylaxis before delivery (n = 18)
there were seven (41%) neonatal intensive care unit admissions,
three preterm births and one baby was cooled for neonatal
encephalopathy.
Conclusions Anaphylaxis is a rare severe complication of
pregnancy and frequently the result of a reaction to antibiotic
administration. This study highlights the seriousness of the
outcomes of this condition for the mother. The low incidence is
reassuring given the large proportion of the pregnant population
that receive prophylactic antibiotics during delivery.
Keywords Anaphylaxis in pregnancy, causal agents, management,
outcomes.
Tweetable abstract Anaphylaxis is a rare severe complication of
pregnancy and frequently the result of a reaction to antibiotic
administration.
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Introduction
Anaphylaxis in pregnancy is a potentially fatal systemic
hypersensitive reaction, which is rapid in onset. It is char-
acterised by life-threatening airway, breathing or circulatory
problems, often with skin or mucosal change. The aetiology
of anaphylaxis in pregnancy includes exposure to allergens
such as antibiotics and latex.1–5 It commonly occurs when
allergens trigger an IgE mechanism causing mast cell activa-
tion, resulting in an anaphylactic reaction.6
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There is very little information regarding the incidence
of anaphylaxis in pregnancy in the UK. A study in the USA
suggested an incidence of 2.7 cases per 100 000 deliveries.7
It has been proposed that anaphylaxis is increasing in the
general population.8,9 This is of particular concern as case
reports indicate that maternal and neonatal outcomes of
anaphylaxis in pregnancy are severe.10,11 Complications
include cardio-respiratory compromise for both the woman
and the infant, and hypoxic brain injury in the neonate.
However, these case reports are unlikely to be representa-
tive of all women with anaphylaxis in pregnancy.
Exposure to antibiotics is increasing in the pregnant pop-
ulation through the use of prophylactic antibiotics before
elective caesarean delivery, and intrapartum antibiotic pro-
phylaxis for group B streptococcal (GBS) carriage to prevent
neonatal transmission,1,2 although routine screening for
GBS carriage is not recommended in the UK.12,13
There are no specific guidelines for the management of
maternal anaphylaxis so it is likely that women with ana-
phylaxis in pregnancy are treated in the same way as those
in the general population.14,15 Management is characterised
by a rapid assessment of life-threatening cardio-respiratory
compromise, which is usually treated with epinephrine,
hydrocortisone, chlorphenamine, oxygen and fluids.16
However, there has been no population-based study to
describe whether this management is used in practice.
Study objective
This study identified a population-based cohort of women
who had anaphylaxis in pregnancy in order to describe the
incidence, causative agents, management and associated
outcomes of this condition.
Methods
Case definition
Anaphylaxis is defined as a severe, life-threatening gener-
alised or systemic hypersensitivity reaction. Cases had to
have at least one of the following criteria: a life-threatening
airway, breathing or circulatory problem (defined in Box 1).
The condition must have been of sudden onset with rapid
progression of symptoms, with skin and/or mucosal changes.
However, during the study it became evident that skin or
mucosal changes were not evident if the management was
rapid. Therefore, all women in whom the final clinical diag-
nosis was anaphylaxis and who met the criteria in Box 1,
irrespective of the presence or absence of skin/mucosal
changes, were included.
Data source
This population-based descriptive study prospectively col-
lected cases of anaphylaxis in pregnancy from all obstetri-
cian-led maternity units in the UK using the UK Obstetric
Surveillance System (UKOSS) between 1 October 2012 and
30 September 2015. The UKOSS methodology has been
described elsewhere.17 In brief, a monthly mailing card was
sent to nominated clinicians in each consultant-led obstet-
ric unit; this card had a simple tick box to signify whether
there had been a case of anaphylaxis in pregnancy that
month in the unit. Clinicians also returned cards if there
had been no cases of anaphylaxis in pregnancy. The ‘nil to
report’ system allowed the differentiation between a non-
response and those where there were truly no cases, which
allowed further follow up of non-responders. Once a case
was reported, the reporting clinician was sent a data collec-
tion form to collect information on demographic charac-
teristics, obstetric history, causative agents, management
and outcomes for each case. No identifiable information
was received and the data were double-entered onto a
bespoke database. Ethics approval for the anonymised
UKOSS data collection was granted by the London Multi-
centre Research Ethics Committee (04/MRE02/45).
This study aimed to assess the incidence of anaphylaxis in
pregnancy in the UK, therefore the study power was gov-
erned by the number of cases occurring. All analyses were
completed using STATA (v13SE, College Station, TX, USA).
The incidence rate with a 95% CI was calculated using
3 years of total maternities in the UK (2012–2014). The
denominator data were obtained from the Office for
National Statistics for England and Wales, NHS digital and
the National Records of Scotland. The mode of delivery
denominator data were obtained from the Hospital Episode
Statistics Analysis, Health and Social Care Information Cen-
tre for England, Patient Episode Database for Wales via the
Welsh Government, Information Service Division for Scot-
land and Northern Ireland Statistics and Research Agency
Box 1. Definitions of clinical criteria
The presence of at least one of the following:
1 A life-threatening airway problem is taken to include:
a Laryngeal or pharyngeal oedema
b Hoarse voice
c Stridor
2 A life-threatening breathing problem is taken to include:
a Shortness of breath and raised respiratory rate
b Wheeze
c Decreased oxygen saturations
d Confusion secondary to hypoxia
e Cyanosis
f Respiratory exhaustion or respiratory arrest
3 A life-threatening circulatory problem is taken to include:
a Signs of shock such as faintness, pallor or clammy skin
b Tachycardia >100 bpm
c Systolic BP <90 mmHg
d Decreasing level of consciousness
e Signs of ischaemia on ECG
f Cardiac arrest
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for 2012–2013, which was extrapolated for the subsequent
years. The results were presented with absolute values and
proportions to describe the characteristics, suspected causa-
tive agents, management and outcomes of the cases. Timing
from symptoms of anaphylaxis to delivery was used to cate-
gorise women into groups according to when the reaction
occurred in relation to the delivery. These were: antepartum,
intrapartum (immediately before delivery), post-delivery
(immediately after delivery) and late postpartum.
Results
During 2012–2015, there were 46 case notifications; of these,
37 women met the case definition. In an estimated
2 324 552 maternities, there was thus an estimated incidence
of 1.6 (95% CI: 1.1–2.2) cases per 100 000 maternities.
Table 1 shows the characteristics and management of
women with anaphylaxis in pregnancy. The mean age of
women was 33 (7 SD) years. Twenty-nine (78%) women
had a history of previous allergic reactions, 16 (43%) with
a history of atopy and two (5%) with a previous anaphy-
lactic reaction. Approximately a third of women (n = 12)
had a known drug allergy and the majority of these
reported allergies related to penicillin-based drugs (n = 10).
The management of the women is presented in Table 1.
High flow oxygen was administered to 29 (81%) women
and intravenous fluids to 32 (86%) women. The majority
of women received epinephrine (n = 28, 93%), chlor-
phenamine (n = 28, 88%) and/or hydrocortisone (n = 33,
97%). Tryptase levels were measured in 31 (84%) women
after resuscitation and were raised in nine (29%).
Women with anaphylaxis in pregnancy were divided into
four groups according to the timing of the reaction (Fig-
ure 1). The majority of reactions occurred intrapartum
(n = 10) or post-delivery (n = 15). There were fewer reac-
tions in the antepartum period (n = 8) and the postpartum
period (n = 4).
For those who had anaphylaxis symptoms in the intra-
partum period, the median time to delivery was 15 minutes
after symptoms of anaphylaxis were first observed (IQR:
6–18). For those who had a caesarean section, the median
time to delivery after a reaction to a prophylactic antibiotic
was 6 minutes (IQR: 4–34). For those who had anaphylaxis
symptoms immediately post-delivery, the median time to
symptoms of anaphylaxis after delivery was 25 minutes
(IQR: 9–64).
In the intrapartum group, seven women had a reaction
to prophylactic antibiotics before a caesarean delivery and
two reacted to anaesthesia (Figure 1). One woman had a
reaction to antibiotics given for GBS prophylaxis and then
proceeded to an immediate caesarean delivery. Nine cae-
sarean deliveries were already planned and there was only
one emergency caesarean delivery as a result of anaphylaxis.
In the post-delivery group, five of these women had a reac-
tion to a prophylactic antibiotics after a caesarean delivery.
In total, 12 women had a reaction to prophylactic antibi-
otics given at the time of caesarean delivery. The incidence
of prophylactic antibiotic-related anaphylaxis associated
with caesarean delivery was 2.1 (95% CI: 1.1–3.6) per
100 000 caesarean deliveries. Overall, half of the women
had a suspected reaction to an antibiotic across all timing
groups (n = 18, 49%). The agents responsible in the anaes-
thetic reactions were: suxamethonium, thiopentone and a
component of spinal anaesthesia.
The anaphylactic reaction was characterised by the
majority of women having either pulmonary or circulatory
symptoms; 24 (65%) additionally had skin or mucosal
changes. The majority of the reactions occurred in the
hospital setting.
Table 1. Characteristics and management of women with
anaphylaxis during pregnancy in the UK between October 2012 and
September 2015 (n = 37)
Characteristics n (%)
Mean age (SD), n = 36 33 (7)
Ethnic group
White 28 (76)
Non-White 9 (24)
Smoking status
Never/ex-smoker 29 (78)
Smoked during pregnancy 8 (22)
Median gestational age at delivery (IQR)*, n = 34 39 (37–40)
Median BMI (IQR), n = 35 26 (23–30)
Previous obstetric history
Parity
0 14 (38)
1 or more 23 (62)
Previous pregnancy problem
Yes 14 (38)
Previous medical history
Previous anaphylactic reaction 2 (5)
Known drug allergy 12 (32)
Type of drug allergy*
Penicillin based 10 (83)
Other 2 (17)
Have a history of allergic reactions 29 (78)
History of atopy 16 (43)
Management*
High flow O2 29 (81)
IV fluids 32 (86)
Epinephrine 28 (93)
Chlorphenamine 28 (88)
Hydrocortisone 33 (97)
Tryptase levels tested
Yes 31 (84)
If yes, Had abnormal tryptase levels 9 (29)
*Percentages are calculated for those with complete data.
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The maternal outcomes for women with anaphylaxis are
shown in Table 2. Two women died (case fatality 5%, 95%
CI: 0.7–18.2%), seven women had one or more additional
severe maternal morbidities, which included three haemor-
rhagic events, two cardiac arrests, one pulmonary embolism
(PE) and one woman had pneumonia. The majority of
poor maternal outcomes occurred in the post-delivery
group (two maternal deaths, one cardiac arrest, three
haemorrhagic events and PE). The agents responsible for
the reactions in the two women who died were suxametho-
nium and co-amoxiclav.
Two women had a pregnancy loss prior to the 3rd tri-
mester and there was one case without delivery informa-
tion, thus delivery data were available for 34 singleton
pregnancies. The infant outcomes are presented in Table 3.
There were no stillbirths. No infants died; however, in
those infants whose mother had anaphylaxis before delivery
there were seven (41%) neonatal intensive care unit admis-
sions, three preterm deliveries and one baby had whole
body cooling for neonatal encephalopathy.
Figure 1. Clinical history of anaphylaxis and suspected causal agent according to time of reaction.
Table 2. Maternal outcomes in women who had anaphylaxis during
pregnancy
Maternal outcomes Reaction
before
delivery,
n = 18 (%)
Reaction
after
delivery,
n = 19 (%)
Total
number = 37,
n (%)
Maternal death 0 2 (11) 2 (5)
Severe maternal
morbidity*
2 (11) 5 (26) 7 (19)
Cardiac arrest 1 (6) 1 (5) 2 (5)
Haemorrhage – 3 (16) 3 (8)
Thrombotic event – 1 (5) 1 (3)
Pneumonia 1 (6) – 1 (3)
ITU admission 5 (28) 9 (47) 14 (38)
*Includes the morbidities of the women who died.
Table 3. Infant outcomes in women who had anaphylaxis during
pregnancy (n = 17*)
Neonatal outcomes Total no.
before
delivery,
n (%)
Group with
prophylactic use
of antibodies prior
to caesarean section
(n = 7), n (%)
Neonatal ICU admission 7 (41) 5 (71)
Neonatal encephalopathy 1 (6) 0
Apgar at 5 minutes <7 0 0
Resuscitation needed
for infant
6 (35) 6 (86)
*One infant had no known delivery information.
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Discussion
Main findings
This study presents national prospective data collected on
women with anaphylaxis in pregnancy. Anaphylaxis is a
severe condition in pregnancy and this study has shown
that it is frequently the result of a reaction to antibiotic
administration. A third of the reactions were as a result of
the prophylactic use of antibiotics at the time of a cae-
sarean section. In total, half of the reactions were due to an
antibiotic. This study highlights the seriousness of the out-
comes of this condition for both women and infants born
as a result of exposure to anaphylaxis. Nevertheless, the
low incidence is reassuring given recent changes in antibi-
otic prophylaxis policies.18 To our knowledge this is the
first national prospective population-based study on ana-
phylaxis in pregnancy and provides population-based data
on the causal agents and outcomes of this severe but rare
condition.
Strength and limitations
The main strength of this study is the use of the UKOSS
methodology, which has provided prospectively collected
population-based data on women with anaphylaxis in preg-
nancy. The adoption of a strict case definition has pre-
vented the inclusion of false-positive cases. However, it is
possible that less severe cases of anaphylaxis were not
reported and the incidence of anaphylaxis may be underes-
timated. A possible limitation is that only 37 cases were
identified; this has resulted in wide confidence intervals in
estimations of incidence and the case fatality rate, even in
this national population-based study.
Interpretation
Incidence
The incidence of anaphylaxis in pregnancy in this study at
1.6 (95% CI: 1.1–2.2) per 100 000 maternities is similar to
that of previously published studies. A study from Texas
using an obstetric database estimated the incidence to be
2.7 per 100 000 deliveries (95% CI: 1.7–4.2).7 Furthermore
in 2003–2005, a study of severe maternal morbidity in
Scotland using data collected from consultant-led units,
estimated the incidence as three cases per 100 000 materni-
ties (95% CI: 1–7).19 In the USA there is routine bacterio-
logical screening for GBS, which has increased the
proportion of women receiving intrapartum antibiotics for
GBS; this is may explain the apparent higher incidence in
the Texan study.20 Other potential reasons include false-
positives in the Scottish and Texan studies.
During 2012–2014, the maternal mortality rate was 8.54
per 100 000 maternities (95% CI: 7.40–9.81).21 In compar-
ison, the maternal mortality rate as a result of anaphylaxis
was 0.09 per 100 000 maternities (95% CI: 0.01–0.30) over
a similar time period.
Causal agents
Twelve reactions were the direct result of prophylactic use
of antibiotics at the time of caesarean delivery which were
administered according to current guidelines.18 Five of
these reactions occurred after caesarean delivery, which is
not a currently recommended practice. This is important;
had the antibiotics been administered before surgery, the
burden of infant morbidity might have been higher.
Similar to previous studies, the most common suspected
causal agent was the use of antibiotics.7,22 Previous studies
showed women developed anaphylaxis after being given
antibiotics prophylactically for GBS,7,23,24 whereas others
were given for surgical prophylaxis.22 Only one woman
developed anaphylaxis following antibiotics for prophylaxis
of GBS in the UK, which may reflect national differences
in antenatal screening policies for GBS between the UK
and some other countries.12,25 Despite both penicillin and
cephalosporin drugs being the most common triggers of a
reaction, they were commonly used in this population.
There is still debate about the optimal choice of antibiotic
for caesarean section prophylaxis.26
Two women who had known penicillin allergies were
given a penicillin-based antibiotic, resulting in an anaphylac-
tic reaction. Human factors have been demonstrated to play
a role in medication errors.27 This highlights that these cases
were preventable and indicates that a detailed drug allergy
history must be taken at booking or prior to administration
of any antibiotics and communicated to the clinical team.
Management
The time from detection of first symptoms of anaphylaxis
to diagnosis was short and mucosal and skin changes did
not occur in 35% of this cohort, which suggests that
prompt management taken by the clinical team prevented
symptoms from progressing. This would suggest that skin
and mucosal changes should not be part of the main case
definition of anaphylaxis.
The causal relationship between anaphylactic reactions
and caesarean delivery has been unclear. Only one woman
had a caesarean delivery as the result of an anaphylactic reac-
tion; this woman received antibiotics for GBS prophylaxis
and then went on to be delivered via caesarean section.
Although the other causal agents (anaesthetics and prophy-
lactic use of antibiotics before a caesarean delivery) were
given before a planned caesarean, the women concerned
went on to have a reaction. Previous studies have shown that
most women with anaphylaxis were delivered by caesarean
section.7,22 A previous review has recommended caesarean
delivery in severe cases of anaphylaxis.22 Caesarean delivery
in this scenario would potentially reduce the risk of hypoxic
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injury in the infant if the woman’s circulatory system were
compromised due to a severe anaphylactic reaction.
The majority of patients were treated according to the
normal anaphylaxis algorithm as they received high level
oxygen, epinephrine, hydrocortisone and chlorphenamine.14
However, national adherence to national guidelines could
be improved, as only 81% received oxygen and 87%
received IV fluids. Consistent with current guidelines,14 our
study results show almost all cases with a recorded
response received epinephrine. In pregnancy it has been
suggested that epinephrine may inhibit utero-placental
blood flow.28 However, fetal survival is maximised through
maternal resuscitation.29 Findings from the Confidential
Enquiry into Maternal Death in the UK recommended that
epinephrine should be the first line treatment for anaphy-
laxis in pregnancy.22,30 In addition, to aid clinical expedi-
ence, the anaphylaxis algorithm should be visible in
operating theatres and labour wards.14,15
Outcomes
Previous studies have been unable accurately to examine
maternal and infant outcomes in this condition due either
to publication bias in case reports22 or to lack of suitable
population-based data.7 This study has shown there are
poor outcomes for women who have anaphylaxis with a
5% case fatality rate and a fifth of women having a severe
morbidity. The confidential enquiry into maternal deaths
in the UK would suggest a similar case fatality rate for ana-
phylaxis during pregnancy, with one death due to anaphy-
laxis during 2006–2008.30
Unlike previous research,28 outcomes were good for the
majority of infants; however, there was one case of neona-
tal encephalopathy which would have resulted in whole
body cooling. Previous research has suggested that poor
outcomes have been averted by rapid diagnosis of anaphy-
laxis, appropriate administration of epinephrine, and
prompt delivery after diagnosis (within 10–15 minutes).22
It would appear that management of maternal anaphylaxis
in this study might explain the low prevalence of poor
neonatal outcomes, noting, however, the wide confidence
intervals around the estimate of neonatal encephalopathy
incidence due to the low numbers.
Conclusions
Anaphylaxis is a rare condition in pregnancy in the UK
and is often the result of antibiotic administration with
severe adverse outcomes for both mother and child. Con-
firmation of the causative agent in all women with a reac-
tion should be undertaken to prevent the prospect of
future anaphylactic reactions. Further efforts are required
to ensure that women with known allergies are not given
drugs they are sensitised to.
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